IMB Dx, Inc.

461030 · KQ · Healthcare / Diagnostics & Research

2,415.00KRW+5.00 (+0.21%)

Price History

Full chart

Market Stats

Previous Close2,410.00

Open2,475.00

Day Range2,360.00 – 2,475.00

52-Week Range1,910.00 – 12,990.00

Volume9.27K

Market Cap41.57B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.51

50-Day Avg2,960.40

200-Day Avg5,842.58

About

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOMr. Tae-You Kim M.D., Ph.D.
Employees0
HeadquartersBYC Highcity Bldg A, Seoul, South Korea, Korea
Websitehttps://www.imbdx.com

Leadership

Mr. Tae-You Kim M.D., Ph.D.Co-Founder & CEO · b. 1961
Du-hee Bang Ph.D.Co-Founder & Chief Scientific Advisor
Peter Moon M.B.A.Co-Founder & Sales Executive Advisor
Mr. Siyeon KimChief Operating Officer · b. 1965
Sang-Hyun Song Ph.D.Chief Scientific Officer
Mr. Hwang-Phill Kim Ph.D.Chief Business Officer · b. 1975
Yongjun Cha M.D.Chief Medical Advisor

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.23B	2.62B	4.03B	3.41B	5.33B
Growth (%)	-	+113.34%	+53.42%	-15.40%	+56.40%
Cost of Revenue	1.20B	2.25B	2.61B	2.52B	3.94B
Gross Profit	31.63M	372.17M	1.42B	888.05M	1.39B
Gross Margin	2.57%	14.18%	35.20%	26.07%	26.02%
Operating Expense	5.31B	9.04B	9.19B	11.50B	10.05B
Operating Income	-5.28B	-8.67B	-7.77B	-10.61B	-8.66B
Operating Margin	-428.97%	-330.23%	-192.92%	-311.47%	-162.60%
EBITDA	-	-7.59B	-7.82B	-7.95B	-6.48B
EBITDA Margin	-	-289.25%	-194.29%	-233.37%	-121.60%
Net Income	-9.79B	-10.44B	-10.42B	-9.58B	-7.93B
Net Income Margin	-795.60%	-397.62%	-258.67%	-281.09%	-148.89%
R&D	3.57B	5.24B	5.77B	7.04B	5.12B
R&D as % of Total Revenue	290.31%	199.63%	143.25%	206.67%	96.10%
Interest Expense	782.68M	1.34B	943.83M	17.68M	24.85M
Interest Expense % of Total Revenue	63.62%	51.17%	23.44%	0.52%	0.47%

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	24.03B	17.35B	9.82B	34.05B	27.12B
Total Liabilities	46.36B	48.48B	1.50B	1.59B	1.96B
Total Equity	-22.33B	-31.13B	8.32B	32.45B	25.16B
Cash	19.32B	5.37B	4.36B	546.91M	2.08B

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-4.01B	-6.33B	-6.23B	-6.65B	-6.20B
Investing Cash Flow	-	-7.39B	5.49B	-28.76B	-
Financing Cash Flow	-	-239.58M	-255.71M	31.58B	-
Capital Expenditure	1.08B	1.75B	504.45M	907.61M	1.00B
Free Cash Flow	-5.10B	-8.07B	-6.74B	-7.55B	-7.20B
FCF to OCF	127.05%	127.59%	108.10%	113.65%	116.16%

Earnings

Report Date	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-
EPS Actual	-164.31	-163.48	-144.53	-126.37	-134.21	-164.69	-140.71	-158.99	-74.12
Surprise	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap41.57B

Enterprise Value21.70B

Trailing P/E0.00

Forward P/E0.00

Price / Sales7.42

Price / Book1.69

Revenue (TTM)5.60B

Gross Profit (TTM)1.57B

EBITDA-7.33B

Profit Margin-135.52%

Operating Margin-93.23%

Return on Equity-28.97%

Return on Assets-19.47%

Shares Outstanding14.33M

Shares Float7.10M

Beta0.51

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%